Logo image of MLSS

MILESTONE SCIENTIFIC INC (MLSS) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:MLSS - US59935P2092 - Common Stock

0.2918 USD
+0 (+0.79%)
Last: 1/15/2026, 8:04:00 PM
0.2858 USD
-0.01 (-2.06%)
Pre-Market: 1/16/2026, 8:49:37 AM
Fundamental Rating

2

MLSS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. MLSS may be in some trouble as it scores bad on both profitability and health. MLSS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year MLSS has reported negative net income.
  • In the past year MLSS has reported a negative cash flow from operations.
  • In the past 5 years MLSS always reported negative net income.
  • MLSS had a negative operating cash flow in each of the past 5 years.
MLSS Yearly Net Income VS EBIT VS OCF VS FCFMLSS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • The Return On Assets of MLSS (-86.63%) is worse than 75.68% of its industry peers.
  • MLSS's Return On Equity of -208.80% is on the low side compared to the rest of the industry. MLSS is outperformed by 72.97% of its industry peers.
Industry RankSector Rank
ROA -86.63%
ROE -208.8%
ROIC N/A
ROA(3y)-57.54%
ROA(5y)-48.91%
ROE(3y)-84.14%
ROE(5y)-67.88%
ROIC(3y)N/A
ROIC(5y)N/A
MLSS Yearly ROA, ROE, ROICMLSS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • MLSS's Gross Margin of 72.80% is amongst the best of the industry. MLSS outperforms 82.16% of its industry peers.
  • In the last couple of years the Gross Margin of MLSS has grown nicely.
  • MLSS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.77%
GM growth 5Y1.76%
MLSS Yearly Profit, Operating, Gross MarginsMLSS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

2

2. Health

2.1 Basic Checks

  • MLSS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MLSS has been increased compared to 1 year ago.
  • Compared to 5 years ago, MLSS has more shares outstanding
  • MLSS has a worse debt/assets ratio than last year.
MLSS Yearly Shares OutstandingMLSS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MLSS Yearly Total Debt VS Total AssetsMLSS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • MLSS has an Altman-Z score of -21.11. This is a bad value and indicates that MLSS is not financially healthy and even has some risk of bankruptcy.
  • MLSS has a Altman-Z score of -21.11. This is amonst the worse of the industry: MLSS underperforms 88.65% of its industry peers.
  • MLSS has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • MLSS's Debt to Equity ratio of 0.25 is in line compared to the rest of the industry. MLSS outperforms 55.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z -21.11
ROIC/WACCN/A
WACC9.87%
MLSS Yearly LT Debt VS Equity VS FCFMLSS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

  • A Current Ratio of 2.03 indicates that MLSS has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.03, MLSS is not doing good in the industry: 60.54% of the companies in the same industry are doing better.
  • MLSS has a Quick Ratio of 2.03. This is a bad value and indicates that MLSS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • MLSS has a Quick ratio of 0.69. This is amonst the worse of the industry: MLSS underperforms 86.49% of its industry peers.
Industry RankSector Rank
Current Ratio 2.03
Quick Ratio 0.69
MLSS Yearly Current Assets VS Current LiabilitesMLSS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 37.92% over the past year.
  • MLSS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.19%.
  • Measured over the past years, MLSS shows a small growth in Revenue. The Revenue has been growing by 0.61% on average per year.
EPS 1Y (TTM)37.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-12.19%
Revenue growth 3Y-5.73%
Revenue growth 5Y0.61%
Sales Q2Q%-6.11%

3.2 Future

  • Based on estimates for the next years, MLSS will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.70% on average per year.
  • The Revenue is expected to grow by 4.17% on average over the next years.
EPS Next Y26.33%
EPS Next 2Y22.07%
EPS Next 3Y9.7%
EPS Next 5YN/A
Revenue Next Year-0.48%
Revenue Next 2Y3.44%
Revenue Next 3Y4.17%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MLSS Yearly Revenue VS EstimatesMLSS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
MLSS Yearly EPS VS EstimatesMLSS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.05 -0.1 -0.15 -0.2 -0.25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MLSS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLSS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLSS Price Earnings VS Forward Price EarningsMLSS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLSS Per share dataMLSS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.07%
EPS Next 3Y9.7%

More info and screens

0

5. Dividend

5.1 Amount

  • MLSS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MILESTONE SCIENTIFIC INC

NYSEARCA:MLSS (1/15/2026, 8:04:00 PM)

Premarket: 0.2858 -0.01 (-2.06%)

0.2918

+0 (+0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)04-13
Inst Owners5.67%
Inst Owner Change0%
Ins Owners2.94%
Ins Owner Change-1.14%
Market Cap22.94M
Revenue(TTM)8.63M
Net Income(TTM)-6.97M
Analysts82.5
Price Target1.02 (249.55%)
Short Float %1.45%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-63.4%
Min EPS beat(2)-96.08%
Max EPS beat(2)-30.72%
EPS beat(4)0
Avg EPS beat(4)-104.25%
Min EPS beat(4)-194.12%
Max EPS beat(4)-30.72%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.25%
Min Revenue beat(2)-12.41%
Max Revenue beat(2)-10.09%
Revenue beat(4)0
Avg Revenue beat(4)-13.44%
Min Revenue beat(4)-25.64%
Max Revenue beat(4)-5.64%
Revenue beat(8)0
Avg Revenue beat(8)-18.46%
Revenue beat(12)3
Avg Revenue beat(12)-10.19%
Revenue beat(16)5
Avg Revenue beat(16)-9.84%
PT rev (1m)0%
PT rev (3m)-38.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)7.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.53
P/FCF N/A
P/OCF N/A
P/B 6.87
P/tB 7.11
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.12
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -86.63%
ROE -208.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.8%
FCFM N/A
ROA(3y)-57.54%
ROA(5y)-48.91%
ROE(3y)-84.14%
ROE(5y)-67.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.77%
GM growth 5Y1.76%
F-Score3
Asset Turnover1.13
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.55%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.03
Quick Ratio 0.69
Altman-Z -21.11
F-Score3
WACC9.87%
ROIC/WACCN/A
Cap/Depr(3y)17.16%
Cap/Depr(5y)20.45%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y26.33%
EPS Next 2Y22.07%
EPS Next 3Y9.7%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.19%
Revenue growth 3Y-5.73%
Revenue growth 5Y0.61%
Sales Q2Q%-6.11%
Revenue Next Year-0.48%
Revenue Next 2Y3.44%
Revenue Next 3Y4.17%
Revenue Next 5YN/A
EBIT growth 1Y-3.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.04%
OCF growth 3YN/A
OCF growth 5YN/A

MILESTONE SCIENTIFIC INC / MLSS FAQ

Can you provide the ChartMill fundamental rating for MILESTONE SCIENTIFIC INC?

ChartMill assigns a fundamental rating of 2 / 10 to MLSS.


What is the valuation status of MILESTONE SCIENTIFIC INC (MLSS) stock?

ChartMill assigns a valuation rating of 0 / 10 to MILESTONE SCIENTIFIC INC (MLSS). This can be considered as Overvalued.


Can you provide the profitability details for MILESTONE SCIENTIFIC INC?

MILESTONE SCIENTIFIC INC (MLSS) has a profitability rating of 1 / 10.


What is the earnings growth outlook for MILESTONE SCIENTIFIC INC?

The Earnings per Share (EPS) of MILESTONE SCIENTIFIC INC (MLSS) is expected to grow by 26.33% in the next year.